The loss was 79 cents a share, compared with 47 cents a share in the year-earlier quarter. Total costs and expenses climbed to $31.4 million from $26.4 million.
Omeros reported product sales of $35.9 million. The company also said sales of Yartemlea, its treatment for stem cell transplant-associated thrombotic microangiopathy, reached $41.8 million in the quarter.
Chief Executive Gregory Demopulos said Yartemlea sales had delivered consecutive quarters of positive operating cash flow.
Omeros fell 9.2% to $15.15 in after-hours trading Monday. The shares had closed down 4.6% at $16.68 and were 2.9% lower for the year.




Comments (0)
No comments yet. Be the first!